GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Net Income

Deep Medicine Acquisition (Deep Medicine Acquisition) Net Income : $-0.61 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Deep Medicine Acquisition's Net Income for the three months ended in Sep. 2023 was $-0.27 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.61 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Deep Medicine Acquisition's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.06.


Deep Medicine Acquisition Net Income Historical Data

The historical data trend for Deep Medicine Acquisition's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition Net Income Chart

Deep Medicine Acquisition Annual Data
Trend Mar21 Mar22 Mar23
Net Income
- -0.41 -0.40

Deep Medicine Acquisition Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 0.58 -0.66 -0.26 -0.27

Deep Medicine Acquisition Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Deep Medicine Acquisition's Net Income for the fiscal year that ended in Mar. 2023 is calculated as

Net Income(A: Mar. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.343+-0.058+0+0.001
=-0.40

Deep Medicine Acquisition's Net Income for the quarter that ended in Sep. 2023 is calculated as

Net Income(Q: Sep. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.27+0+0+0
=-0.27

Net Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Deep Medicine Acquisition  (NAS:DMAQ) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Deep Medicine Acquisition's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Deep Medicine Acquisition Net Income Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
595 Madison Avenue, 12th Floor, New York, NY, USA, 10017
Website
Deep Medicine Acquisition Corp is a blank check company.
Executives
John Chiang director 3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen director, officer: Chief Executive Officer C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo officer: Chief Financial Officer 40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc 10 percent owner 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017

Deep Medicine Acquisition (Deep Medicine Acquisition) Headlines

From GuruFocus

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By GlobeNewswire GlobeNewswire 10-24-2022

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By Value_Insider Value_Insider 10-24-2022